Successful use of trastuzumab with anthracyclinebased chemotherapy followed by trastuzumab maintenance in patients with advanced her2positive gastric cancer sofia palacio, arturo loaizabonilla, muaiad kittaneh, christos kyriakopoulos, roberto e. Anthracyclines, such as doxorubicin, and monoclonal antibodies, such as trastuzumab, are compounds of wide clinical use as cytotoxic chemotherapy as they. Pdf cardiotoxicidad reversible en una mujer con 54 anos. In four of the five studies, trastuzumab followed anthracycline administration, and prospective cardiac function monitoring was included in all of the trials. To our knowledge, this is the first report of trastuzumab induced hepatotoxicity requiring discontinuation of the drug. Rt is known to reduce the risk of lrr, meaning the reappearance of the cancer in and around the original site of disease. Trastuzumab may significantly improve survival among women with advanced breast cancer, but there are concerns about cardiotoxicity associated with this targeted therapy. Cardiotoxicity of trastuzumab given for 12 months compared. Bevacizumab y trastuzumab son dos anticuerpos monoclonales. The incidence rates were % when the antibody was administered in combination with paclitaxel and 27% when it was administered with an anthracycline. Management of cardiac health in trastuzumabtreated patients. Mar 27, 2017 trastuzumab is a therapy that targets her2, a protein which is overexpressed in 1525% of breast cancers.
A retrospective study of possible risk and protective factors, abstract objective. Trastuzumab with or without tamoxifen in treating women with. Its use, however, results in a small to modest risk. Nov 20, 2012 trastuzumab is a monoclonal antibody that targets the human epidermal growth factor receptor tyrosine kinase her2erbb2. The current analysis examines this issue and means to prevent cardiac events among women receiving trastuzumab. Cardiotoxicidad por quimioterapia pdf download citation on researchgate on dec 1, edwin arevalo guerrero and others published rol del strain miocardico en. Quizlet flashcards, activities and games help you improve your grades. This agent has shown a highly significant antitumour effect for patients with her2positive breast cancer, and is now considered part of the standard regimens for the treatment of this disease in both the metastatic and adjuvant setting. Trastuzumab is a monoclonal antibody that targets the human epidermal growth factor receptor 2 her2, also called erbb2. For the 15 to 20 percent of patients with breast cancer whose tumors overexpress her2, trastuzumab therapy is important in the treatment of both early and advanced disease.
Although adjuvant trastuzumab improves survival in patients with her2positive early breast cancer, there is growing concern about the longterm effect of trastuzumab induced. Ochoa, mauricio escobar, belisario arango, maria h. Patients receive trastuzumab herceptin iv over 6090 minutes on day 1. Tener una fevi basal con ecografia 3 d idealmente o ecografia 2 d. In spite of the therapeutic benefits of trz, cardiotoxic side effects are still an issue. Although generally well tolerated, patients may develop symptomatic or asymptomatic cardiotoxicity, forcing a discontinuation of treatment, therefore preventing patients from benefiting from maximal disease control. Trastuzumabe herceptin, zedora biossimilar apresentacao. Concern about cardiac safety influenced the design of trials evaluating trastuzumab in early breast cancer. Cardiotoxicity profile of trastuzumab springerlink. Symptomatic heart failure, a serious adverse effect of trastuzumab, occursin 1% to 4% of patients treated with the antibody, whereas left ventricular ejection fraction declines substantially in 10% of patients. Cardiotoxicidad por antraciclicos berenice vicente. Patients receive trastuzumab as in arm i and oral tamoxifen once daily on days 121. Trastuzumab, a drug targeting human epidermal growth factor receptor 2, improves survival rate in women with metastatic breast cancer. Assistant professor of medicine department of breast medical oncology.
Successful use of trastuzumab with anthracyclinebased. Trastuzumab 440 mg20 ml en ampula oncologia info medicamento. Cardiotoxicity associated with trastuzumab treatment of her2. Cardiotoxicidade associada a terapeutica oncologica.